GNLX
Genelux CorporationNASDAQHealthcare$2.57+0.39%ClosedMarket Cap: $96.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
8.79
P/S
12836.77
EV/EBITDA
-3.03
DCF Value
$0.10
FCF Yield
-25.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-3537.5%
Operating Margin
-415175.0%
Net Margin
-401812.5%
ROE
-153.3%
ROA
-168.9%
ROIC
-251.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $8.0K | -1750.0% | $-9.4M | $-9.2M | $-0.25 | — |
| FY 2025 | $8.0K | -7075.0% | $-33.2M | $-32.1M | $-0.86 | — |
| Q3 2025 | $0.00 | NaN% | $-8.2M | $-8.0M | $-0.21 | — |
| Q2 2025 | $0.00 | -Infinity% | $-7.8M | $-7.5M | $-0.20 | — |
| Q1 2025 | $0.00 | NaN% | $-7.8M | $-7.5M | $-0.21 | — |
| Q4 2024 | $0.00 | NaN% | $-9.7M | $-9.0M | $-0.27 | — |
| FY 2024 | $8.0K | -11187.5% | $-31.7M | $-29.9M | $-0.95 | — |
| Q3 2024 | $0.00 | NaN% | $-6.9M | $-6.5M | $-0.19 | — |
| Q2 2024 | $0.00 | -Infinity% | $-6.9M | $-6.6M | $-0.22 | — |
| Q1 2024 | $8.0K | -3000.0% | $-8.1M | $-7.8M | $-0.29 | — |
| Q4 2023 | $0.00 | NaN% | $-7.0M | $-6.8M | $-0.25 | — |
| FY 2023 | $170.0K | -498.8% | $-24.2M | $-28.3M | $-1.16 | — |